$Lexicon Pharmaceuticals (LXRX.US)$ Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) Tuesday, 18th February at 8:00 am Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 20...
$Lexicon Pharmaceuticals (LXRX.US)$ Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Lexicon Pharmaceuticals (LXRX) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin). The drug was intended as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This decision was anticipated, aligning with Lexicon's previous s...
$Lexicon Pharmaceuticals (LXRX.US)$Tomorrow they get a second at bat for FDA approval! Last go round they were issued a CRL! Well here we are quite a ways removed from that first PDUFA calendar date! IMO since this is a redo. Hehehe! IMO that does make a ( NORMALLY ) bit better odds of a approval! But in this case at the pre meeting it didn’t look very positive! Also the answer can come anytime between tomorrow/Friday all the way to Monday!
NOTE! 1. NFA 2. Do not open position without chart confirmation, indicators, momentum. 3. Check current shorts availability on FINTEL.io 4. Scale out and secure profits 5. Always remember shorts include dark pools. 6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you. 7. I DO NOT give buy or sell advice 8. COH (cash on hand); AH (after hours): RTH (regular trading hours) $Aadi Biosciences (AADI.US)$PR AH 12/...
$Lexicon Pharmaceuticals (LXRX.US)$ “New PDUFA date is expected to be December 20, 2024. Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.” nfa
4
Report
james beets
:
Alot of those who voted no noted it's help in certain subgroups of patients, so limited approval will still be decent!
Lnova
OP
james beets
:
“Key Insights Lexicon Pharmaceuticals' significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public The top 2 shareholders own 62% of the company Institutional ownership in Lexicon Pharmaceuticals is 33% Every investor in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) should be aware of the most powerful shareholder groups. With 48% stake, private equity firms possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.” Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 24% Drop, Institutions Also Suffered Losses
Lexicon Pharmaceuticals Stock Forum
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Tuesday, 18th February at 8:00 am
Data reinforce unique clinical advantages of sotagliflozin
Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin
THE WOODLANDS, Texas, Feb. 18, 20...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Lexicon Pharmaceuticals (LXRX) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin). The drug was intended as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This decision was anticipated, aligning with Lexicon's previous s...
come on fdaaaaaaaaaa
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
“New PDUFA date is expected to be December 20, 2024. Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.”
nfa
No comment yet